Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2025 Earnings Call Transcript

Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2025 Earnings Call Transcript

Seeking Alpha • 12 hours ago

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution

– ARCALYST ® (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively – – ARCALYST 2026 net product revenue expected to be $900 - $920 million – – KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026 – – KPL-1161 Phase 1 trial planned to initiate by the end of 2026 – – Cash balance increased by $170.4 million in 2025 to $414.1 million –       – Conference call and webcast scheduled for 8:30 am ET today – LONDON, Feb. 24, 2026 (GLOBE NEWSWIRE) --  – Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today reported fourth quarter and full year 2025 financial results and recent portfolio execution. “Kiniksa continued to drive significant advancements across its commercial and clinical portfolio in 2025.

GlobeNewsWire • 16 hours ago

Kiniksa Pharmaceuticals International, plc (KNSA) Misses Q4 Earnings Estimates

Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.29 per share. This compares to a loss of $0.12 per share a year ago.

Zacks Investment Research • 13 hours ago

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

LONDON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 24, 2026 at 8:30 a.m. Eastern Time to report its fourth quarter and full year 2025 financial results and recent portfolio execution.

GlobeNewsWire • Feb 19, 2026

Kiniksa Pharmaceuticals International, plc (KNSA) Earnings Expected to Grow: Should You Buy?

Kiniksa Pharmaceuticals International, plc (KNSA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Feb 17, 2026

Kiniksa: Arcalyst Is The Engine, But KPL-387 Is The Accelerator

Kiniksa transitions from survival risk to growth, targeting dominance in the pericarditis market with robust cash flow and expanding margins. KNSA's Arcalyst drives revenue growth, with 2026 guidance of $900–$920 million, approaching blockbuster status and supporting self-funding operations. Pipeline evolution with KPL-387 aims to improve adherence, capture full economics, and expand the addressable market, with Phase 2 data in H2 2026 as a key catalyst.

Seeking Alpha • Jan 24, 2026

Kiniksa Pharmaceuticals International, plc (KNSA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Kiniksa Pharmaceuticals International, plc (KNSA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 13, 2026

Kiniksa Pharmaceuticals Provides Corporate Update

– ARCALYST ® (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth – – ARCALYST 2026 net product revenue expected to be $900 - $920 million – – KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026 – – KPL-1161 Phase 1 trial planned to initiate by year end – – Cash balance increased by $170.4 million in 2025 to $414.1 million (unaudited) –

GlobeNewsWire • Jan 12, 2026

Kiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference

LONDON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time).

GlobeNewsWire • Jan 7, 2026

Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London

LONDON, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will present at the Jefferies Global Healthcare Conference in London on Monday, November 17, 2025 at 2:30 p.m. Greenwich Mean Time (9:30 a.m.

GlobeNewsWire • Nov 12, 2025